Skip to main content

Table 2 Multiple designs of targeting nanodrugs for HER2-positive breast cancer

From: Nanotechnology approaches to addressing HER2-positive breast cancer

Nanoparticle Targeting mechanism Cancer therapy Multifunction capability References
Pluronic-based nanocarrier loaded with iron oxide nanoparticles Chitosan conjugated/HER2 targeting Doxorubicin Iron oxide for MRI imaging, Cy5.5 for imaging, doxorubicin for anticancer therapy Choi et al. (2015)
PEGylated phospholipid nanobubble Herceptin targeting HER2 receptors None Can potentially deliver anticancer therapy, has ultrasonography capability for imaging Jiang et al. (2016)
Mini-nanodrug, co-ligand poly(beta-L-malic acid) (PMLA) HER2-mRNA-annealing oligonucleotide None Functionalization for drugs, targeting peptides, protective PEG, peptides for destabilizing membranes and dyes for imaging Ding et al., 2017
Novel humanized HER2 antibody Anti-HER2 antibody None Can be used in many targeting applications. Has advantages over traditional antibodies Cao et al. (2015)
HER2 aptamer-conjugated gold nanostar 42-base pair HER2 aptamer for targeting HER2 receptors Reduction of HER2 receptors due to lysosome degradation This HER2 aptamer gold nanostar can be used for detection while offering drug delivery Lee et al. (2015)
Antibody-conjugated gold–gold sulfide nanoparticle Anti-HER2 antibody conjugated for targeting HER2 receptors Photothermal therapy Simultaneously provides targeting contrast agents for imaging and photothermal therapy Day et al. (2010)
Iron oxide nanoparticle Small exocyclic peptide from the 185HER2/neu monoclonal antibody trastuzumab. conjugated for targeting HER2 receptors Paclitaxel None Mu et al. (2015)